Caribou Biosciences, Inc.
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
CRBU | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 2929 7TH STREET, SUITE 105, 94710 BERKELEY
- Website:
- https://www.cariboubio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company developing transformative, genome-edited cell therapies. A leader in the CRISPR field, the company utilizes its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology to engineer complex, multiplex edits with high precision and specificity. Its primary focus is on creating allogeneic, or "off-the-shelf," CAR-T cell therapies for patients with hematologic malignancies and other devastating diseases. A key component of its strategy is "armoring" these therapies through genome editing techniques, such as immune cloaking and checkpoint disruption, to enhance their persistence and anti-tumor activity. The company was co-founded by CRISPR pioneer and 2020 Nobel laureate Jennifer Doudna.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Caribou Biosciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Caribou Biosciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Caribou Biosciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
